First Time Loading...

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 135.9 USD -0.75% Market Closed
Updated: Apr 28, 2024

Ascendis Pharma A/S
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Operating Income Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
BIOPOR
SANION

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Operating Income
-€447.7m
CAGR 3-Years
-11%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Operating Income
kr5.3B
CAGR 3-Years
-6%
CAGR 5-Years
31%
CAGR 10-Years
54%
Zealand Pharma A/S
CSE:ZEAL
Operating Income
-kr561.2m
CAGR 3-Years
2%
CAGR 5-Years
-4%
CAGR 10-Years
-12%
B
Bavarian Nordic A/S
CSE:BAVA
Operating Income
kr2.1B
CAGR 3-Years
75%
CAGR 5-Years
N/A
CAGR 10-Years
51%
Bioporto A/S
CSE:BIOPOR
Operating Income
-kr60.2m
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
-12%
Saniona AB
STO:SANION
Operating Income
-kr79.3m
CAGR 3-Years
21%
CAGR 5-Years
-8%
CAGR 10-Years
N/A

See Also

What is Ascendis Pharma A/S's Operating Income?
Operating Income
-447.7m EUR

Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Operating Income amounts to -447.7m EUR.

What is Ascendis Pharma A/S's Operating Income growth rate?
Operating Income CAGR 5Y
-24%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Ascendis Pharma A/S have been -11% over the past three years , -24% over the past five years .